Akebia Therapeutics Book Value Per Share Growth & History (AKBA)
Akebia Therapeutics's book value per share was $0.12 for fiscal 2025.
View full Akebia Therapeutics company overviewAkebia Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.12 | $0.34 | — |
| 2024 | 2024-12-31 | -$0.22 | -$0.06 | — |
| 2023 | 2023-12-31 | -$0.16 | -$0.19 | — |
| 2022 | 2022-12-31 | $0.03 | -$0.39 | −93.21% |
| 2021 | 2021-12-31 | $0.42 | -$1.23 | −74.66% |
| 2020 | 2020-12-31 | $1.65 | -$1.58 | −48.89% |
| 2019 | 2019-12-31 | $3.23 | -$2.21 | −40.65% |
| 2018 | 2018-12-31 | $5.44 | $2.87 | +111.33% |
| 2017 | 2017-12-31 | $2.57 | $0.81 | +45.94% |
| 2016 | 2016-12-31 | $1.76 | -$2.51 | −58.71% |
| 2015 | 2015-12-31 | $4.27 | -$0.84 | −16.38% |
| 2014 | 2014-12-31 | $5.11 | $96.97 | — |
| 2013 | 2013-12-31 | -$91.86 | $52.04 | — |
| 2012 | 2012-12-31 | -$143.90 | — | — |
Akebia Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.09 | -$0.02 | −17.13% |
| Q1 2026 | 2026-03-31 | $0.10 | $0.01 | +8.77% |
| Q4 2025 | 2025-12-31 | $0.12 | $0.34 | — |
| Q3 2025 | 2025-09-30 | $0.16 | $0.40 | — |
| Q2 2025 | 2025-06-30 | $0.11 | $0.27 | — |
| Q1 2025 | 2025-03-31 | $0.09 | $0.22 | — |
| Q4 2024 | 2024-12-31 | -$0.22 | -$0.06 | — |
| Q3 2024 | 2024-09-30 | -$0.24 | -$0.03 | — |
| Q2 2024 | 2024-06-30 | -$0.16 | -$0.02 | — |
| Q1 2024 | 2024-03-31 | -$0.13 | -$0.03 | — |
| Q4 2023 | 2023-12-31 | -$0.16 | -$0.19 | — |
| Q3 2023 | 2023-09-30 | -$0.21 | -$0.25 | — |
| Q2 2023 | 2023-06-30 | -$0.14 | -$0.46 | — |
| Q1 2023 | 2023-03-31 | -$0.10 | -$0.23 | — |
| Q4 2022 | 2022-12-31 | $0.03 | -$0.39 | −93.21% |
| Q3 2022 | 2022-09-30 | $0.04 | -$0.74 | −94.29% |
| Q2 2022 | 2022-06-30 | $0.32 | -$0.71 | −68.83% |
| Q1 2022 | 2022-03-31 | $0.12 | -$1.23 | −90.87% |
| Q4 2021 | 2021-12-31 | $0.42 | -$1.23 | −74.66% |
| Q3 2021 | 2021-09-30 | $0.79 | -$1.43 | −64.58% |
| Q2 2021 | 2021-06-30 | $1.03 | -$1.56 | −60.21% |
| Q1 2021 | 2021-03-31 | $1.35 | -$1.69 | −55.66% |
| Q4 2020 | 2020-12-31 | $1.65 | -$1.58 | −48.89% |
| Q3 2020 | 2020-09-30 | $2.22 | -$1.72 | −43.60% |
| Q2 2020 | 2020-06-30 | $2.59 | -$1.79 | −40.83% |
| Q1 2020 | 2020-03-31 | $3.04 | -$1.79 | −37.07% |
| Q4 2019 | 2019-12-31 | $3.23 | -$2.21 | −40.65% |
| Q3 2019 | 2019-09-30 | $3.93 | $1.43 | +57.43% |
| Q2 2019 | 2019-06-30 | $4.37 | $1.46 | +49.97% |
| Q1 2019 | 2019-03-31 | $4.84 | $1.37 | +39.50% |
| Q4 2018 | 2018-12-31 | $5.44 | $2.87 | +111.33% |
| Q3 2018 | 2018-09-30 | $2.50 | $0.38 | +18.18% |
| Q2 2018 | 2018-06-30 | $2.92 | $1.57 | +117.33% |
| Q1 2018 | 2018-03-31 | $3.47 | $2.68 | +339.63% |
| Q4 2017 | 2017-12-31 | $2.57 | $0.81 | +45.94% |
| Q3 2017 | 2017-09-30 | $2.11 | -$0.52 | −19.69% |
| Q2 2017 | 2017-06-30 | $1.34 | -$2.17 | −61.75% |
| Q1 2017 | 2017-03-31 | $0.79 | -$3.63 | −82.17% |
| Q4 2016 | 2016-12-31 | $1.76 | -$2.51 | −58.71% |
| Q3 2016 | 2016-09-30 | $2.63 | -$2.18 | −45.29% |
| Q2 2016 | 2016-06-30 | $3.51 | -$1.68 | −32.37% |
| Q1 2016 | 2016-03-31 | $4.42 | -$0.20 | −4.33% |
| Q4 2015 | 2015-12-31 | $4.27 | -$0.84 | −16.38% |
| Q3 2015 | 2015-09-30 | $4.81 | -$0.78 | −14.02% |
| Q2 2015 | 2015-06-30 | $5.18 | -$0.81 | −13.57% |
| Q1 2015 | 2015-03-31 | $4.62 | -$1.69 | −26.77% |
| Q4 2014 | 2014-12-31 | $5.11 | $96.97 | — |
| Q3 2014 | 2014-09-30 | $5.60 | — | — |
| Q2 2014 | 2014-06-30 | $6.00 | — | — |
| Q1 2014 | 2014-03-31 | $6.31 | — | — |
| Q4 2013 | 2013-12-31 | -$91.86 | — | — |
Akebia Therapeutics book value per share trends
Over the last five fiscal years, Akebia Therapeutics's book value per share decreased from $1.65 to $0.12, a change of -$1.53. The latest reported quarter, Q2 2026, shows $0.09.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Akebia Therapeutics source filings ↗